ストックスクリーナーアプリを入手
10.97
5.94%
0.615
アフターアワーズ：
10.96
-0.010
-0.09%
Abcellera Biologics Inc (ABCL) 最新ニュース
AbCellera Director Michael R. Hayden Donates 50,000 Shares to Charity via Genworks 2 Consulting - Kalkine Media
AbCellera Biologics Announces Oversubscribed $200 Million Offering - TipRanks
AbCellera Enters Underwriting Agreement for $187M Equity Offering With Jefferies, J.P. Morgan - TradingView
AbCellera Biologics (NASDAQ:ABCL) Sees Large Volume IncreaseTime to Buy? - MarketBeat
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile - AOL.com
Funding Roundup: Silence Therapeutics, AbCellera Announce IPO Pricing, Beyang, Remepy Close Series A Financing - Pharmaceutical Executive
Abcellera Biologics Inc Nasdaq ABCL Canada F-35 Fighter Jet Purchase (hA9yM7fsuE) - Mshale
ABCL Looks 82.6% Overvalued on GF Value™ - GuruFocus
AbCellera prices $200 million public offering at $9.75/share - Investing.com
AbCellera prices $200 million public offering at $9.75/share By Investing.com - Investing.com Nigeria
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants - lincolnjournal.com
AbCellera (ABCL) Q2 2026 Earnings Call Transcript - AOL.com
AbCellera Biologics stock analysis: momentum vs. fundamentals By Investing.com - Investing.com Canada
AbCellera Biologics stock analysis: momentum vs. fundamentals - Investing.com
What's Going on With AbCellera Biologics Stock On Wednesday? - Benzinga
AbCellera Biologics (NASDAQ:ABCL) Shares Gap DownHere's Why - MarketBeat
Revenue Downgrade: Here's What Analysts Forecast For AbCellera Biologics Inc. (NASDAQ:ABCL) - Moomoo
National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stoc - Benzinga
ABCL News | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL) - ChartMill
AbCellera offers up USD 200m in stock to support NK3 menopause antibody - AllSci
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
ABCL StockAbCellera Biologics Inc Stock Breaking News Today | ABCL Stock Price Ifc (po852VQ6WV) - Mshale
AbCellera’s ABCL635 Meets Primary Endpoints in Phase 2 for Menopause Symptoms - The Clinical Trial Vanguard
AbCellera Biologics (ABCL) Stock Sees Fair Value Lift After Clinical Data And Jazz Deal - Yahoo Finance
AbCellera Biologics (ABCL) On ABCL635 Trial Results And A Richer Valuation Story - simplywall.st
AbCellera Biologics | 424B5: Prospectus - Moomoo
AbCellera Biologics Inc. • Robinhood Token (ABCL) Price Prediction for 2026 to 2031 - Bybit
Truist raises AbCellera stock price target on trial results By Investing.com - Investing.com South Africa
AbCellera launches $200-million equity offering on heels of strong menopause trial results - The Globe and Mail
AbCellera launches $200 million public offering of common shares By Investing.com - Investing.com UK
ABCL Looks 72.1% Overvalued on GF Value™ - GuruFocus
Why is Abcellera Biologics stock sliding today? - Investing.com
AbCellera Biologics (ABCL) Could Be 33% Overvalued Following ABCL635 Phase 2 Results - Yahoo Finance
AbCellera stock falls on $200M public offering launch By Investing.com - Investing.com India
AbCellera stock falls on $200M public offering launch - Investing.com
AbCellera: Excellent Phase 2 Data In Menopause But The Platform Narrative Is Fading - Seeking Alpha
AbCellera launches $200 million public offering of common shares - Investing.com
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Business Wire
ABCL Maintained by Truist Securities -- Price Target Raised to $30 - GuruFocus
AbCellera Shares Jump on Trial Results Amid Interest in Menopause Drugs - Moomoo
Truist Financial Issues Positive Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock Price - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 8.7%Here's What Happened - MarketBeat
Truist raises AbCellera stock price target on trial results - Investing.com
This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News. -- Barrons.com - moomoo.com
AbCellera Biologics (ABCL) Gets Its First Pipeline Win With Positive Phase 2 Data - Yahoo! Finance Canada
AbCellera stock surges on ABCL635 menopause Phase 2 trial results - qz.com
AbCellera’s menopause medicine ‘sets new efficacy bar’ for hot flashes - BioSpace
Is AbCellera Biologics (ABCL) Fully Valued After Its 172% Run? - Yahoo Finance
AbCellera Soars Nearly 40% as Menopause Drug Data ‘Wows’ Analysts - NAI500
ABCL635, a drug for hot flash treatment, shows positive results in mid-stage trials; AbCellera Biologics (ABCL.US) surges in response - Bitget
Positive results from the mid-stage trial of the hot flash treatment drug ABCL635, AbCellera Biologics (ABCL.US) surges in response - Bitget
AbCellera (ABCL) Rockets 44% as Hot Flash Treatment Brightens Growth Outlook - Yahoo Finance
AbCellera stock soars 35% on successful clinical trial result - Business in Vancouver
AbCellera Biologics | 8-K: Current report - Moomoo
AbCellera Jumps 32% After Menopause Drug Slashes Hot Flashes in Phase 2 Trial - finance.biggo.com
This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 34% on Good News. - Barron's
Hot-Flash Drug Trial Result Sends AbCellera Up as Much as 41% - Bloomberg.com
ABCL Looks 64.1% Overvalued on GF Value™ Amid Promising Clinical News - GuruFocus
AbCellera Biologics Sees Unusually High Options Volume (NASDAQ:ABCL) - MarketBeat
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profi - StreetInsider
AbCellera Biologics (NASDAQ:ABCL) Reaches New 12-Month HighStill a Buy? - MarketBeat
Abcellera Biologics stock hits 52-week high at 8.79 USD By Investing.com - Investing.com South Africa
Abcellera Biologics stock hits 52-week high at 8.79 USD - Investing.com
Why is Abcellera Biologics stock surging today? - Investing.com
0.03%
0.33%
大文字化:
|
ボリューム (24 時間):